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Introduction: The morbidity associated with ablative condition-
ing has prevented the widespread application of bone marrow (BM)
transplantation (BMT) to treat autoimmune diseases and hemo-
globinopathies. To reduce the risk-beneﬁt ratio of establishing
chimerism, less-toxic approaches for conditioning recipients have
been pursued. As one approaches the threshold for conditioning,
failure of durable chimerism occurs with an increasing frequency.
In the present studies, we evaluated the effect of non-ablative
conditioning regimens on sensitization after graft failure and BM
re-transplantation. Materials and Methods: Recipients were in-
fused with MHC-disparate BMC in the context of costimulatory
molecule blockade. In the primary BMT, B6 (H-2b) mice were
treated with anti-
-TCR mAb (day-3) and/or anti-CD154 (day0
and day3), but without any total body irradiation (TBI), then
transplanted with 15  106 allogeneic BALB/c (H-2d) BM cells.
Secondary BMT was performed 5-7 weeks after primary BMT
with 950 cGy TBI and 15  106 BALB/c BM cells. Results: As
expected, engraftment did not occur in mice after primary BMT.
All animals survived. After secondary BMT with 950 cGy TBI
conditioning, engraftment occurred in 25% of mice treated with
anti-
TCR alone at primary BMT. In contrast, all mice engrafted
after secondary BMT with initial treatment of anti-
TCR plus
anti-CD154, and 75% of mice engrafted with anti-CD154 treat-
ment alone at the ﬁrst BMT. Flow cytometry cross-match assay
was performed to detect anti-donor Abs in the sera collected 4
weeks after the ﬁrst BMT. The values are reported as mean
ﬂuorescence intensity (MFI). The Ab titers were 4.92.6 MFI in
mice treated with anti-CD154 and 4.00.4 in mice treated with
both anti-
TCR and anti-CD154 resembled the Ab level in naı¨ve
mice (3.40.5). Ab titers were signiﬁcantly higher in mice treated
with anti-
TCR mAb alone (47.771.3; P0.05) and the non-
mAb treated group (12334.7).Conclusion:These results suggest
that CD154:CD40 co-stimulatory blockade used at the time of
primary BMT promotes allogeneic engraftment in secondary
BMT after engraftment failure. The mechanism is that anti-
CD154 inhibits B cell activation and generation of alloantibody
after primary BMT. Circulating anti-donor Abs are therefore the
critical hurdle for the success of secondary BMT. These ﬁndings
could have a signiﬁcant impact on management of clinic recipients
who have failed at primary BMT and require retransplantation.
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THE IMPACT OF EARLY ONSET OF HEMOPHAGOCYTOSIS AFTER
TRANSPLANTATION ON THE OUTCOME OF ALLOGENIC STEM CELL
TRANSPLANTATION
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[Introduction] Recently, the concept of early onset of hemoph-
agocytosis after transplantation has been proposed, but the inci-
dence, pathological ﬁndings and prognosis have not clariﬁed. We
analyzed how the early onset of hemophagocytosis after transplan-
tation affects the outocome of allogenic stem cell transplantation.
[Patients and methods] Fifty-two patients received their trans-
plants at the Nagoya First Red Cross Hospital from May 2005 to
April 2006. Forty-ﬁve patients of the 52 patients received marrow
aspiration in early stage of transplantation (until day30), and were
included in the current study. Patients’ ages were from 17 to 65
(median 42) years old. Forty patients were malignant diseases, and
5 patients were non-malignant diseases. Nineteen patients received
reduced intensity stem cell transplantation (RIST) regimen, and 36
patients received conventional regimen. Thirty-two patients re-
ceived BMT, 8 patients received PBSCT, and 5 patients did CBT.
Clots of bone marrow were retrospectively analyzed by a pathol-
ogist, and they were divided into three groups according to the
intensity of pathological ﬁndings of hemophagocytosis as group A
(no hemophagocytosis), group B (mild hemophagocytosis) , and
group C (severe hemophagocytosis). We compare three groups
with the clinical parameters.
[Results] Twenty-two patients were included in group A (49%),
13 patients in group B (29%), and 10 patients in group C (22%).
The average of maximum T-bilirubin in early stage of transplan-
tation (until day 30) was 1.60 mg/dl (group A), 2.68 mg/dl (group
B), and 6.49 mg/dl (group C).There was signiﬁcant difference
between A group to C group (p0.01). Similarly, the average of
maximum creatinine was 0.78 mg/dl (group A), 0.75 mg/dl (group
B), and 1.26 mg/dl (group C). There was signiﬁcant difference
between A group and B group to C group (p0.01). Disease free
survival until day 100 was 4.5% (group A), 7.7% (group B) and
40% (group C) (p0.02).
[Conclusion] It is supposed that the occurrence of hemophago-
cytosis until day 30 were well associated with elevation of T-
bilirubin and creatinine, and early mortality. To conﬁrm a clinical
signiﬁcance of hemophagocytosis, farther studies are needed.
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ALTERATION OF NK TOLERANCE EARLY POST-ALLOGENEIC HEMATO-
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Donor NK alloreactivity can play a signiﬁcant role in hema-
topoietic cell transplantation (HCT) outcome by decreasing
leukemia relapse and increasing survival. How NK cells in HCT
behave through killer Ig-like receptor (KIR) recognition of
target cell HLA has been the subject of discussion, with evi-
dence supporting a “missing self HLA” mechanism, relevant to
KIR ligand incompatible (HLA-mismatched) HCT, and other
studies supporting a “missing HLA ligand” mechanism, relevant
to both HLA-matched and mismatched HCT. We propose that
in HCT these two mechanisms need not be mutually exclusive.
Using 6-color ﬂow cytometric analysis of intracellular IFN-
production, we evaluated the response of inhibitory KIR-ex-
pressing NK subsets following activation with 721.221, a target
cell line deﬁcient in class I expression, or with 721.221 trans-
fectants expressing the KIR ligands HLA-Cw3, -Cw4, or -Bw4.
NK cells from 10 KIR haplotype-A homozygous individuals and
from 7 T-cell depleted HCT donor-recipient pairs were evalu-
ated. In normal individuals, mature NK cells expressing inhib-
itory KIR speciﬁc for self-HLA were signiﬁcantly more respon-
sive to target cells lacking KIR ligand than NK cells expressing
inhibitory KIR for non-self HLA (P0.001), consistent with
“missing self” behavior. NK cells expressing KIR2DL3, 2DL1,
and 3DL1 all demonstrated similar response patterns, which
were predictable based on the HLA background of the individ-
ual. However, NK cells from HCT patients displayed signiﬁ-
cantly different response patterns to the same target cells: com-
pared to the NK subsets in the donor, the recipient NK
response to lack of HLA ligand, both self and non-self, was higher
at days 15-60 (P0.001), decreasing to donor levels by day 100.
Indeed, the response of NK cells speciﬁc for non-self HLA early
post-HCT was equivalent to the response of NK cells speciﬁc
for self-HLA in a normal individual. Thus, while the mature
NK cell achieves tolerance by preferentially endowing func-
tional competence to inhibitory KIR speciﬁc for self-HLA
(“missing self”), the stem cell-derived NK cell post-HCT
achieves this self-tolerance only after transitioning from a state
where all inhibitory KIR receptors are capable of recognizing
lack of ligand (“missing ligand”). These results indicate that NK
alloreactivity in HCT is driven by both mechanisms and that
HLA-identical HCT recipients beneﬁt from NK alloreactivity
early post-HCT due to lack of HLA ligand for donor inhibitory
KIR.
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